ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. 

As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. 

Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.  

Bpifrance

Kurma Partners

EQT life science

Idinvest Partners

Wellington Partners

Pfizer Venture Investments

Kinled Holding

Boehringer Ingelheim Venture Fund

Agent Capital

Alexandria Venture Investments

Gimv

Pureos Bioventures

Earlybird Venture Capital

Leukemia & Lymphoma Society

Eurazeo

Invus

ImCheck Therapeutics

Today, on International Women's Day, ImCheck Therapeutics proudly stands with women everywhere, celebrating the remarkable resilience of the women who drive innovation and progress within our organization. 
To the women on our team. Your talent, dedication and fearlessness are the driving force behind our success. We applaud your courage and commitment to excellence.
To our women leaders. Thank you for paving the way and inspiring the next generation of talent with grace. Your vision and determination are invaluable assets to our company.
On this special day, let's continue to champion equality and diversity in the workplace and recognize the collective strength that propels us forward.
 
Together, we can create a more inclusive and empowering environment for all!

In celebration of the 9th International Day of Women and Girls in Science, we salute and celebrate an oustanding team of women who have acted and continue to act as agents of change to accelerate innovation, development and change in our organization. 

Your contributions have shaped this company and we commend your courage, talent and fearlessness. 

To our leaders, we salute you for charting the course, for being trailblazers and for showing our junior employees that they too can pursue their dreams.  

From all of us at ImCheck... Thank You ! 

R&D based company focused on manufacturing of drugs for multiple therapeutic areas

Recursion

Company focused on the treatment of various conditions such as cancer, infectious diseases

Tizona Therapeutics

Company focused on developing novel immuno-oncology therapeutics targeting specific immune cells

NexImmune

Company involved in the development of therapeutics for dermatological conditions

Dermavant Sciences

Company specializing in providing scientific consulting services for drug development

Metrum Research Group

Company focused on the development of innovative cancer therapies

Clovis Oncology

Imcheck Therapeutics is a biotechnology company developing ICT41, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9Vδ2 T cells to combat infectious diseases.

Imcheck Therapeutics

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 6, 2024 7:52 AM	d2e61a0f
public peers	general	May 6, 2024 7:52 AM	5345a74b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:52 AM	e78d57eb
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	ee6605bd
crunchbase profile	general
li profile	general	May 6, 2024 7:52 AM	b6a83098
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 6, 2024 7:52 AM	2afc34be
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:IMCHECKTHERAPEUTICS

Imcheck Therapeutics